- Home
- NERV vs NLSP Comparison
NERV vs NLSP Comparison
Compare NERV & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- NLSP
- Stock Information
- Founded
- NERV 2007
- NLSP 2015
- Country
- NERV United States
- NLSP Switzerland
- Employees
- NERV N/A
- NLSP N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- NLSP Health Care
- Exchange
- NERV Nasdaq
- NLSP Nasdaq
- Market Cap
- NERV 12.0M
- NLSP 12.4M
- IPO Year
- NERV 2014
- NLSP 2021
- Fundamental
- Price
- NERV $2.15
- NLSP $1.98
- Analyst Decision
- NERV Hold
- NLSP
- Analyst Count
- NERV 1
- NLSP 0
- Target Price
- NERV $5.00
- NLSP N/A
- AVG Volume (30 Days)
- NERV 12.9K
- NLSP 193.3K
- Earning Date
- NERV 11-04-2025
- NLSP 10-17-2025
- Dividend Yield
- NERV N/A
- NLSP N/A
- EPS Growth
- NERV N/A
- NLSP N/A
- EPS
- NERV 1.48
- NLSP N/A
- Revenue
- NERV N/A
- NLSP N/A
- Revenue This Year
- NERV N/A
- NLSP N/A
- Revenue Next Year
- NERV N/A
- NLSP N/A
- P/E Ratio
- NERV $1.46
- NLSP N/A
- Revenue Growth
- NERV N/A
- NLSP N/A
- 52 Week Low
- NERV $1.15
- NLSP $1.30
- 52 Week High
- NERV $2.98
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- NERV 48.19
- NLSP 41.39
- Support Level
- NERV $2.06
- NLSP $1.88
- Resistance Level
- NERV $2.25
- NLSP $2.29
- Average True Range (ATR)
- NERV 0.11
- NLSP 0.12
- MACD
- NERV -0.03
- NLSP -0.01
- Stochastic Oscillator
- NERV 24.19
- NLSP 37.26
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.